Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

Allergan rebuffs Valeant once again

Allergan rebuffs Valeant once again Botox-maker Allergan issued a statement yesterday saying it has unanimously rejected the third offer by Valeant and Pershing Square Capital - which values it at more than $53bn - saying once again

Pharma deals during May 2014

Pharma deals during May 2014 This sale clears potential anti-trust issues if Valeant acquires Allergan with its Botox franchise.

Valeant steps up pressure on Allergan with raised bid

Valeant steps up pressure on Allergan with raised bid Ups price yet again in attempt to acquire company behind Botox. ... The Botox manufacturer is concerned that Valeant's explosive growth in recent years, fuelled by a string of acquisitions and funded by taking on a lot of debt, means it could

Valeant sweetens Allergan offer with help from Nestle deal

Valeant sweetens Allergan offer with help from Nestle deal The Canadian company is offering $58.30 a share for Botox (onabotulinumtoxinA) manufacturer Allergan - $10 up on its earlier bid - and has also agreed to divest a portfolio of skincare assets ... to Nestle for $1.4bn that includes Botox rival Dysport

Battle lines drawn as Allergan rejects Valeant offer

Battle lines drawn as Allergan rejects Valeant offer Quebec-based Valeant has however reiterated its determination to complete the deal and gain control of Allergan, which has built a thriving business on the back of wrinkle treatment Botox (onabotulinumtoxinA)

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics